Últimas noticias sobre Tharimmune (NASDAQ:THAR) Bolsa

Tharimmune

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Tharimmune Inc

Tharisa PLC

Tesla CEO Elon Musk has long been vocal about his views on U.S. immigration policy, advocating for increased legal immigration while calling for tougher enforcement against illegal crossings. 
During a September 2023 visit to the U.S.-Mexico border, Musk underscored his stance, arguing that America should welcome hardworking immigrants but must also uphold the law. This complex view on immigration, shaped by his own experiences as an immigrant, has sparked significant attention.
An often-overlooked chapter of Musk's life involves his early years in the U.S. when he and his brother, Kimbal Musk, were building their first startup, Zip2.
Also Read: <a href="https://www.benzinga.com/general/entertainment/24/09/41084606/elon-musk-targets-lopsided-anti-trump-donations-by-netflix-employees-as-cancellations-soare">Elon Musk Targets &#8216;Lopsided&#8217; Anti-Trump Donations By Netflix Employees As Cancellations Soared After Co-Founder Reed Hastings Donated To Kamala Harris</a>
What Happened: In a 2013 Milken Institute event, Kimbal Musk openly shared that both he and Elon were &#8220;illegal immigrants&#8221; during the launch of Zip2 — their first U.S.-based company, <a href="https://www.cnn.com/2024/09/29/us/elon-musk-immigration-gray-area-cec/index.html">CNN </a>reports. 
Elon Musk interjected, calling the situation a &#8220;gray area.&#8221; Still, the anecdote highlights a less-discussed chapter in his personal immigration journey.
It is unclear what kind of visas they had at the time.
According to CNN, investors helped the Musk brothers secure legal status shortly after funding arrived.
More recently, Elon Musk aligned his views with those of JPMorgan Chase CEO Jamie Dimon, who warned that failure to control the border would &#8220;destroy our country.&#8221; Musk echoed Dimon's sentiments on X, agreeing that border control is <a href="https://www.benzinga.com/news/24/09/41017982/elon-musk-agrees-with-jamie-dimon-if-you-do-not-control-the-borders-you-are-going-to-destroy-our-cou">critical to national security.</a>
Why It Matters: Elon Musk's personal immigration story, particularly the details shared by his brother, adds complexity to his vocal stance on immigration reform. His calls for stricter enforcement of U.S. immigration laws, juxtaposed with the challenges he faced as an immigrant entrepreneur, reflect the broader challenges many face within the current system.
 This background also resonates with voters, as immigration remains a key issue heading into the 2024 presidential election.
Musk's influence, especially through his platform X, continues to drive significant public discourse around the need for legal immigration reforms while addressing illegal immigration concerns. His agreement with Dimon on border security amplifies the debate, positioning Musk as a central figure in this conversation. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41083814/mark-cuban-warns-elon-musk-that-when-the-time-comes-he-needs-trump-the-most-he-will-find-out-the-tru">Mark Cuban Warns Elon Musk That When The Time Comes He Needs Trump The Most He Will Find Out The Truth: &#8216;His Loyalty Is Only To Himself&#8217;</a></li>
</ul>
Photo: Shutterstock

General

Elon Musk's Brother Once Said They Were 'Illegal Immigrants' During Startup's Early Days

Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) shares are trading lower by 5.3% to $39.20 during Monday&#8217;s session. Shares of auto supplier stocks may be under pressure following <a href="https://www.benzinga.com/markets/equities/24/09/41089577/whats-going-on-with-stellantis-stock-monday">weak guidance</a> from Stellantis, which could be causing concern for the sector.
What Happened: Shares of Advance Auto Parts fell sharply Monday, following the announcement from Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) that the global automaker revised its fiscal 2024 guidance.
The Stellantis report, which sent shockwaves across the auto sector, also led to declines in other major automakers like General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), with market concerns growing over weakened auto sales, supply chain constraints, and profitability.
Read Also: <a href="https://www.benzinga.com/etfs/sector-etfs/24/09/41098327/longshoremen-strike-looms-standoff-could-cost-1b-a-day-leave-thanksgiving-prep-in-a-pinch">Longshoremen Strike Looms, Standoff Could Cost $1B A Day, Leave Thanksgiving Prep In A Pinch</a>
Stellantis, the parent company of brands like Chrysler, Dodge and Jeep, cut its adjusted operating margin expectations to a range of 5.5%-7.0%, down from its prior double-digit growth targets. The company also projected negative industrial free cash flow for fiscal 2024, between -€5 billion to -€10 billion, a stark contrast to previous expectations of positive cash flow. 
These financial adjustments are attributed to substantial shipment declines in North America, increased incentives on aging vehicle inventories, and overall deterioration in global market conditions, which many analysts believe could signal broader challenges for the automotive and aftermarket parts industries.
What Else: Advance Auto Parts, a leading provider of aftermarket automotive parts, is particularly sensitive to fluctuations in the broader automotive sector. While the company primarily caters to the DIY market and professional repair shops, any slowdown in new car sales and production impacts the demand for aftermarket parts. 
Stellantis' announcement of declining shipments — now expected to reduce by over 200,000 vehicles in the second half of 2024 — suggests fewer cars on the road and in need of parts over the near term. 
Additionally, the increased incentives to push older model-year vehicles could mean reduced profitability for automakers, which often translates into leaner inventory and less need for replenishment in parts.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41100587/s-p-500-etf-titans-drive-691b-in-2024-inflows-nasdaq-bitcoin-etfs-close-behind">S&amp;P 500 ETF Titans Drive $691B In 2024 Inflows: Nasdaq, Bitcoin ETFs Close Behind</a>
<h2 class="wp-block-heading">Is AAP A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/AAP">Advance Auto Parts</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Advance Auto Parts does pay a dividend, which yields 1.64% per year as of the closing price on Sep. 30, 2024. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 8.89%, you'll need to buy a share of Allspring Inc Opps by the Oct. 15, 2024. Once done, you can expect to receive a nominal payout of $0.05 on Nov. 1, 2024.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/AAP">Advance Auto Parts</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AAP has a 52-week high of $88.56 and a 52-week low of $37.51.

News

STLA

Why Advance Auto Parts (AAP) Stock Is Trading Lower

Deep-pocketed investors have adopted a bullish approach towards First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FSLR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 36 extraordinary options activities for First Solar. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 58% leaning bullish and 33% bearish. Among these notable options, 12 are puts, totaling $701,960, and 24 are calls, amounting to $2,315,304.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $120.0 to $310.0 for First Solar during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for First Solar's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across First Solar's significant trades, within a strike price range of $120.0 to $310.0, over the past month.
<h3>First Solar Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727723732_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$23.0</td>
<td>$22.6</td>
<td>$22.6</td>
<td>$270.00</td>
<td>$1.0M</td>
<td style="text-align: right;">234</td>
<td style="text-align: right;">453</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$28.95</td>
<td>$28.7</td>
<td>$28.95</td>
<td>$280.00</td>
<td>$133.1K</td>
<td style="text-align: right;">438</td>
<td style="text-align: right;">46</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$153.95</td>
<td>$152.0</td>
<td>$153.9</td>
<td>$120.00</td>
<td>$123.2K</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$45.5</td>
<td>$45.3</td>
<td>$45.3</td>
<td>$280.00</td>
<td>$117.7K</td>
<td style="text-align: right;">123</td>
<td style="text-align: right;">26</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$10.55</td>
<td>$10.35</td>
<td>$10.48</td>
<td>$250.00</td>
<td>$111.9K</td>
<td style="text-align: right;">737</td>
<td style="text-align: right;">155</td>
</tr>
</tbody>
</table>

<h3>About First Solar</h3>
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
Following our analysis of the options activities associated with First Solar, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of First Solar</h3>
<ul>
<li>Currently trading with a volume of 895,483, the FSLR's price is down by -2.56%, now at $249.2. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 29 days.</li>
</ul>
<h3>Professional Analyst Ratings for First Solar</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $321.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Truist Securities downgraded its action to Buy with a price target of $300. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on First Solar, maintaining a target price of $343. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for First Solar, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

FSLR

A Closer Look at First Solar's Options Market Dynamics

Deep-pocketed investors have adopted a bullish approach towards Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LOW usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Lowe's Companies. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 42% leaning bullish and 23% bearish. Among these notable options, 7 are puts, totaling $283,740, and 14 are calls, amounting to $1,548,705.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $240.0 to $300.0 for Lowe's Companies over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Lowe's Companies's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Lowe's Companies's whale trades within a strike price range from $240.0 to $300.0 in the last 30 days. 
<h3>Lowe's Companies Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727723727_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.9</td>
<td>$20.8</td>
<td>$20.8</td>
<td>$270.00</td>
<td>$424.2K</td>
<td style="text-align: right;">51</td>
<td style="text-align: right;">486</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$20.75</td>
<td>$20.7</td>
<td>$20.7</td>
<td>$270.00</td>
<td>$335.3K</td>
<td style="text-align: right;">51</td>
<td style="text-align: right;">852</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$20.8</td>
<td>$20.7</td>
<td>$20.7</td>
<td>$270.00</td>
<td>$134.5K</td>
<td style="text-align: right;">51</td>
<td style="text-align: right;">486</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$20.95</td>
<td>$20.4</td>
<td>$20.7</td>
<td>$270.00</td>
<td>$124.2K</td>
<td style="text-align: right;">51</td>
<td style="text-align: right;">179</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.9</td>
<td>$20.4</td>
<td>$20.7</td>
<td>$270.00</td>
<td>$105.5K</td>
<td style="text-align: right;">51</td>
<td style="text-align: right;">290</td>
</tr>
</tbody>
</table>

<h3>About Lowe's Companies</h3>
Lowe's is the second-largest home improvement retailer in the world, operating more than 1,700 stores in the United States, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.
Following our analysis of the options activities associated with Lowe's Companies, we pivot to a closer look at the company's own performance.
<h3>Lowe's Companies's Current Market Status</h3>
<ul>
<li>With a trading volume of 913,772, the price of LOW is up by 0.61%, reaching $268.77.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 50 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Lowe's Companies</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $291.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Melius Research downgraded its action to Buy with a price target of $290. 
&#x2A; An analyst from TD Cowen persists with their Hold rating on Lowe's Companies, maintaining a target price of $265. 
&#x2A; An analyst from Oppenheimer has elevated its stance to Outperform, setting a new price target at $305. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Lowe's Companies, which currently sits at a price target of $307. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lowe's Companies options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Market Whales and Their Recent Bets on LOW Options

Whales with a lot of money to spend have taken a noticeably bearish stance on JPMorgan Chase.
Looking at options history for JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) we detected 60 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 43 are puts, for a total amount of $2,869,780 and 17, calls, for a total amount of $1,617,064.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $155.0 to $225.0 for JPMorgan Chase over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for JPMorgan Chase's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of JPMorgan Chase's whale activity within a strike price range from $155.0 to $225.0 in the last 30 days. 
<h3>JPMorgan Chase 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727723722_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.5</td>
<td>$2.45</td>
<td>$2.46</td>
<td>$225.00</td>
<td>$492.0K</td>
<td>13.8K</td>
<td>2.2K</td>
</tr>
<tr>
<td>JPM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.85</td>
<td>$3.75</td>
<td>$3.8</td>
<td>$180.00</td>
<td>$380.0K</td>
<td>2.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>JPM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.3</td>
<td>$200.00</td>
<td>$215.0K</td>
<td>4.0K</td>
<td>543</td>
</tr>
<tr>
<td>JPM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$12.6</td>
<td>$12.4</td>
<td>$12.4</td>
<td>$200.00</td>
<td>$186.0K</td>
<td>753</td>
<td>150</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$56.7</td>
<td>$56.7</td>
<td>$56.7</td>
<td>$160.00</td>
<td>$119.0K</td>
<td>871</td>
<td>21</td>
</tr>
</tbody>
</table>

<h3>About JPMorgan Chase</h3>
JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with nearly $4.1 trillion in assets. It is organized into four major segments--consumer and community banking, corporate and investment banking, commercial banking, and asset and wealth management. JPMorgan operates, and is subject to regulation, in multiple countries.
Having examined the options trading patterns of JPMorgan Chase, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of JPMorgan Chase</h3>
<ul>
<li>With a volume of 4,170,048, the price of JPM is down -0.59% at $209.25. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
<h3>Expert Opinions on JPMorgan Chase</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $227.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Deutsche Bank downgraded its action to Hold with a price target of $235. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on JPMorgan Chase, maintaining a target price of $220. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for JPMorgan Chase with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

JPMorgan Chase Options Trading: A Deep Dive into Market Sentiment

Shares of General Motors Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) are experiencing declines amid broad weakness in the auto sector following Stellantis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) <a href="https://www.benzinga.com/markets/equities/24/09/41089577/whats-going-on-with-stellantis-stock-monday">lowering its full-year 2024 guidance.</a>
What To Know: Stellantis has revised its adjusted operating margin expectations to a range of 5.5%–7.0%, a drop from the double-digit growth previously forecasted. Additionally, the company now anticipates industrial free cash flow for fiscal 2024 to fall between negative €5 billion and negative €10 billion, reversing its earlier positive outlook.
This revision comes as Stellantis faces challenges with North American performance and broader global industry deterioration. The automaker is taking several remedial steps, including cutting North American shipments by over 200,000 vehicles in the second half of 2024—double the previous guidance of 100,000—while increasing incentives on older model-year vehicles to stimulate demand. These actions follow the company's earlier report of a 14% revenue decline in the first half of 2024, with net profit dropping by 48%.
GM And F Price Action: General Motors shares were down by 2.61% at $44.80 and Ford shares were down by 2.41% at $10.52 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Image via Unsplash.

Why Are General Motors And Ford Shares Trading Lower Today

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor&#39;s dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.
Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company&#39;s earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.
<h2>Unitil in Focus</h2>
Headquartered in Hampton, Unitil (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/utl#NYSE">UTL</a>) is a Utilities stock that has seen a price change of 13.54% so far this year. The utility is paying out a dividend of $0.43 per share at the moment, with a dividend yield of 2.85% compared to the Utility - Electric Power industry&#39;s yield of 3.24% and the S&amp;P 500&#39;s yield of 1.52%.
Taking a look at the company&#39;s dividend growth, its current annualized dividend of $1.70 is up 4.9% from last year. In the past five-year period, Unitil has increased its dividend 5 times on a year-over-year basis for an average annual increase of 2.77%. Any future dividend growth will depend on both earnings growth and the company&#39;s payout ratio; a payout ratio is the proportion of a firm&#39;s annual earnings per share that it pays out as a dividend. Unitil&#39;s current payout ratio is 56%. This means it paid out 56% of its trailing 12-month EPS as dividend.
Looking at this fiscal year, UTL expects solid earnings growth. The Zacks Consensus Estimate for 2024 is $2.92 per share, representing a year-over-year earnings growth rate of 3.55%.
<h2>Bottom Line</h2>
Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. It&#39;s important to keep in mind that not all companies provide a quarterly payout.
High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, UTL is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold).
<a href="https://www.zacks.com/stock/news/2343529/why-unitil-utl-is-a-great-dividend-stock-right-now?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-2343529">To read this article on Zacks.com click here.</a>

Dividends

Small Cap

Trading Ideas

Why Unitil Is A Great Dividend Stock Right Now

Stocks slid Monday after Federal Reserve Chairman Jerome Powell said that future interest rate cuts would depend on economic data during his appearance at the National Association of Business Economics. While Powell noted inflation is moving closer to the Fed&#8217;s 2% target and highlighted positive economic progress, his comments on data-driven rate decisions added uncertainty to the market just weeks after <a href="https://www.benzinga.com/news/24/09/41068393/inflation-decline-strengthens-confidence-in-feds-interest-rate-cut-if-you-were-second-guessing-the-f">a recent rate cut.</a>
What Happened: Powell appeared at the National Association of Business Economics (NABE) in Nashville, Tennessee, where <a href="https://www.benzinga.com/news/24/09/41085958/fed-chair-jerome-powell-set-to-speak-as-economists-raise-concerns-over-risks-arising-from-potential">he gave prepared remarks</a> and took part in a fireside conversation sharing details on the recent interest rate cut, inflation, the housing market and what's next for the Fed in November.
"Our economy is strong overall and has made progress," Powell said.
Powell said "inflation has eased" and "labor market conditions are solid."
The Fed Chairman said inflation is on a sustainable path back to 2%, and the recent 50-basis point rate cut shows growing confidence in the goal.
"Our focus was on bringing down inflation."
Powell said the Fed's patient approach to rate cuts "has paid dividends."
Speaking on the labor market, Powell said the strength of the labor market "can be maintained" and that unemployment rates are well within estimates.
"Over the past year, we have continued to see solid growth and healthy gains in the labor force and in productivity."
Powell said one of the Fed's main goals is not to have higher unemployment, as they bring inflation down.
"We have made a good deal of progress."
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a">Interest Rates In Free-Fall: What It Means For Mortgages, Credit Cards And Your Wallet As The Federal Reserve Springs Into Action For First Time In 4 Years</a>
What's Next: Powell said the Federal Reserve is not on a pre-set course to decide on further rate cuts at the November meeting.
"Overall, the economy is in solid shape. We intend to use our tools to keep it there," Powell said.
The Fed Chairman said decisions will be made on a meeting-by-meeting basis.
Powell said the goal is to see income and savings rates go up after it appears that consumers are spending more than their income.
For future interest rate cuts, Powell said the process will play out over time and does not need to happen fast.
"Will depend on the data."
Powell said the rate cuts can happen slower or faster depending on how the economy moves.
Ahead of the November meeting there will be several key pieces of data, which include reports on inflation and unemployment. Powell said the Fed will "take everything into account."
"Looking forward, if the economy evolves broadly as expected, policy will move over time toward a more neutral stance."
Market Reaction: The stock market dripped slightly, following Powell's comments. The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, was trading around $571.12 at the time Powell began talking and is trading at $570.50 at the time of publication.
The Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) trades at $485.03 at the time of writing, down 0.35% on the day.
The SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) is down 0.44% to $421.08 at the time of publication Monday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/09/41031059/after-fed-rate-cuts-is-tesla-nvidia-apple-or-amazon-the-best-investment-poll-reveals-top-magnif">After Fed Rate Cuts, Is Tesla, Nvidia, Apple, Or Amazon The Best Investment? Poll Reveals Top Magnificent 7 Stock</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Econ #s

Federal Reserve

SPDR Dow Jones Industrial Average ETF Trust

Stocks Slip As Powell Says Future Interest Rate Cuts Hinge On Data: 'Economy Is In Solid Shape, We Intend To Use Our Tools To Keep It There'

In a speech at Token2049, Edward Snowden, the former NSA contractor turned whistleblower, addressed the evolving landscape of digital privacy, government control and the <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38616885/bitcoins-clock-is-ticking-why-edward-snowden-issues-final-warning">role of cryptocurrency</a> in shaping a new world order.
What Happened: Pointing on how government is exerting control over digital platforms, Snowden cited the <a href="https://www.benzinga.com/news/24/09/40893281/telegram-ceo-pavel-durov-faces-10-year-sentence-and-500k-fine-in-frances-first-cybercrime-case-under">recent case of Telegram&#8217;s founder Pavel Durov.</a> He <a href="https://www.youtube.com/watch?v=XD-XU6Y3TfA">stated,</a> "We saw a well-coordinated effort by the old powers to gain control over Telegram by taking its founder Durov as frankly a hostage in France."
The whistleblower emphasized the importance of designing systems that resist state interference, praising Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies for their approach. He argued, &#8220;You have to design your app so that there will never be a head that the state can point a gun at, or they will do it."
Snowden expressed concern about the increasing attempts by governments to control digital communication, mentioning the European Union's chat control proposal. He warned, &#8220;They're laying the procedural framework for the global control the voices of every volume and that&#8217;s what it&#8217;s really about.&#8221;
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41011761/former-coinbase-cto-balaji-srinivasan-says-bitcoin-is-about-stopping-the-state-from-slowly">Former Coinbase CTO Balaji Srinivasan Says Bitcoin Is About Stopping The State From Slowly Draining Your Wealth</a>
Why It Matters: Addressing the crypto community, Snowden urged a focus on the core values of cryptocurrency, stating, "We need to talk about the ruling values of the system the crypto part of cryptocurrency that&#8217;s what makes it special." He cautioned against diluting these principles to appease institutional investors.
Snowden also touched on the potential dangers of emerging technologies, including AI and consumer electronics. He stressed the importance of decentralization and privacy in these areas.
Snowden called for a return to the foundational principles of cryptocurrency, stating, "We should defy bureaucracy, we should reject modernity. Embrace tradition and you&#8217;ll save the world." 
What&#8217;s Next: The influence of <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a> is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41009065/bitwise-cio-matt-hougan-the-most-powerful-people-in-finance-are-allocating-to-crypto">Bitwise CIO Matt Hougan: &#8216;The Most Powerful People In Finance Are Allocating To Crypto&#8217;</a></li>
</ul>
Image: Flickr

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Edward Snowden Cautions Crypto Industry Not To Dilute Principles: 'We Should Defy Bureaucracy'

WIIM

MUFG

SMFG

Shares of Japanese banking companies are trading higher amid a rise in the price of the yen. Incoming Prime Minister Shigeru Ishiba announced plans for a snap election on October 27, shortly after his recent election victory.

Over the past 24 hours, Internet Computer's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ICP</a>) price has fallen 5.87% to $9.1. This is opposite to its positive trend over the past week where it has experienced a 5.0% gain, moving from $8.7 to its current price. 
The chart below compares the price movement and volatility for Internet Computer over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1727723021_0.png" alt="price_chart" />
The trading volume for the coin has risen 12.0% over the past week diverging from the circulating supply of the coin, which has decreased 0.03%. This brings the circulating supply to 471.58 million. According to our data, the current market cap ranking for ICP is #28 at $4.30 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1727723021_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

$ICP

Cryptocurrency Internet Computer Down More Than 5% Within 24 hours

Over the past 24 hours, Wrapped Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WBTC</a>) price has fallen 3.78% to $63,179.00. This is opposite to its positive trend over the past week where it has experienced a 1.0% gain, moving from $63,204.70 to its current price. 
The chart below compares the price movement and volatility for Wrapped Bitcoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1727722952_0.png" alt="price_chart" />
The trading volume for the coin has decreased 19.0% over the past week, while the overall circulating supply of the coin has decreased 0.17% to over 152 thousand. This puts its current circulating supply at an estimated 100.0% of its max supply, which is 152 thousand. The current market cap ranking for WBTC is #16 at $9.67 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1727722952_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$WBTC

Wrapped Bitcoin Decreases More Than 3% Within 24 hours

Over the past 24 hours, Polkadot's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/dot/usd">DOT</a>) price has fallen 5.72% to $4.53. This is opposite to its positive trend over the past week where it has experienced a 3.0% gain, moving from $4.42 to its current price. 
The chart below compares the price movement and volatility for Polkadot over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1727722943_0.png" alt="price_chart" />
Polkadot's trading volume has climbed 12.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.07%. This brings the circulating supply to 1.42 billion. According to our data, the current market cap ranking for DOT is #20 at $6.43 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1727722943_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$DOT

Polkadot Down More Than 5% Within 24 hours

Stellantis Recalling 190,000 Plug-in Hybrid Jeep Wrangler, Grand Cherokee Vehicles For Fire Risks

Truist Securities raised the price target for Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says it &#8220;is impressive and difficult to ignore.&#8221;
Korlym (mifepristone) is a prescription medicine used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and who cannot have surgery or for whom surgery has failed.&nbsp;
Cushing syndrome is&nbsp;a hormonal disorder that occurs when the body has too much cortisol, a hormone that helps the body respond to stress.&nbsp;
Truist analyst notes approximately 20K Cushing&#8217;s disease (pituitary adenoma) patients in the U.S., of which ~10K are adequately managed with surgical resection of the pituitary adenoma.
Medical management is recommended for the remaining 10K. Therefore, there&#8217;s still significant room for growth, with just ~2,000 hypercortisolism patients currently on Korlym.
In June, Teva Pharmaceuticals Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reportedly sued Corcept Therapeutics, accusing it of a monopoly on Korlym.
The lawsuit, filed in federal court in San Francisco, alleges that Corcept and its sole distributor, Optime Care, engaged in anti-competitive practices <a target="_blank" href="https://www.benzinga.com/24/06/39339275/concerpt-therapeutics-shares-are-trading-lower-what-you-need-to-know" rel="noreferrer noopener">to stifle competition</a>.
In May,&nbsp;Corcept Therapeutics announced that the GRACE Phase 3 trial of&nbsp;relacorilant&nbsp;in patients with hypercortisolism (Cushing&#8217;s syndrome)&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/39039282/why-mid-cap-corcept-therapeutics-stock-trading-higher-on-tuesday" rel="noreferrer noopener">met its primary endpoint</a>.
The company is conducting a Phase 3 GRADIENT trial for relacorilant with enrolled adrenal adenoma patients to strengthen the case for treating patients whose hypercortisolism was driven by adrenal adenoma.
Data from GRACE and GRADIENT studies will form a part of the FDA application submission. The analyst says, &#8220;GRADIENT is well-powered for success.&#8221;
Truist notes that Corcept Therapeutics can achieve around $3 billion in total revenue within five years.
The analyst highlights that management emphasized that once relacorilant is approved, almost all existing patients on Korlym would be converted to relacorilant.
With increased market penetration of relacorilant in Cushing&#8217;s from 16% to 25% in 2033, Truist raised the price target from $65 to $76, <a target="_blank" href="https://www.benzinga.com/quote/CORT/analyst-ratings" rel="noreferrer noopener">with a Buy rating</a>.
Price Action: CORT stock is up 5.19% at $46.21 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41101457/optimism-around-aquestive-as-it-moves-forward-with-severe-allergy-baldness-candidat" target="_blank" rel="noreferrer noopener">Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate</a>.</li>
</ul>

Analyst Color

Price Target

Reiteration

Analyst Ratings

CORT

TEVA

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast

In the preceding three months, 7 analysts have released ratings for Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $222.86, along with a high estimate of $260.00 and a low estimate of $197.00. This current average represents a 6.7% decrease from the previous average price target of $238.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1727722878_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Inspire Medical Systems among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$197.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$236.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$217.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Inspire Medical Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Inspire Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Inspire Medical Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Inspire Medical Systems's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INSP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Inspire Medical Systems analyst ratings.</a>
<h2>About Inspire Medical Systems</h2>
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
<h3>Understanding the Numbers: Inspire Medical Systems's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Inspire Medical Systems's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 29.65% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Inspire Medical Systems's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.6%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Inspire Medical Systems's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.38% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Inspire Medical Systems's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INSP

Analyst Scoreboard: 7 Ratings For Inspire Medical Systems

Over the past 24 hours, Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price has fallen 3.75% to $63,336.00. This continues its negative trend over the past week where it has experienced a 0.0% loss, moving from $63,379.45 to its current price. 
The chart below compares the price movement and volatility for Bitcoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1727722874_0.png" alt="price_chart" />
The trading volume for the coin has tumbled 7.0% over the past week along with the circulating supply of the coin, which has fallen 0.09%. This brings the circulating supply to 19.76 million, which makes up an estimated 94.1% of its max supply of 21.00 million. According to our data, the current market cap ranking for BTC is #1 at $1.25 trillion.
<img src="https://www.benzinga.com/files/images/story/2024/1727722874_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bitcoin Down More Than 3% Within 24 hours

Ratings for Webster Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $53.6, a high estimate of $57.00, and a low estimate of $51.00. Experiencing a 3.94% decline, the current average is now lower than the previous average price target of $55.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1727722870_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Webster Finl's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$54.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Ken Usdin</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$51.00</td>
<td>$56.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Webster Finl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Webster Finl compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Webster Finl's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Webster Finl's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WBS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Webster Finl analyst ratings.</a>
<h2>All You Need to Know About Webster Finl</h2>
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
<h3>Breaking Down Webster Finl's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Webster Finl faced challenges, resulting in a decline of approximately -8.71% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 28.55%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.07%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Webster Finl's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.23%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.44.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 5 Takes On Webster Finl

Throughout the last three months, 8 analysts have evaluated Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Viper Energy, presenting an average target of $50.5, a high estimate of $57.00, and a low estimate of $44.00. This current average has increased by 7.45% from the previous average price target of $47.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1727722851_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Viper Energy is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$54.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Aaron Bilkoski</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Viper Energy. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Viper Energy compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Viper Energy's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Viper Energy's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VNOM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Viper Energy analyst ratings.</a>
<h2>Unveiling the Story Behind Viper Energy</h2>
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties primarily in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
<h3>Viper Energy's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Viper Energy's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 34.85%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: Viper Energy's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 26.22% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Viper Energy's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.23% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Viper Energy's ROA stands out, surpassing industry averages. With an impressive ROA of 1.44%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Viper Energy's debt-to-equity ratio stands notably higher than the industry average, reaching 0.92. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VNOM

Analyst Ratings For Viper Energy

Analysts' ratings for Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) over the last quarter vary from bullish to bearish, as provided by 29 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Airbnb, presenting an average target of $128.03, a high estimate of $190.00, and a low estimate of $90.00. A 13.12% drop is evident in the current average compared to the previous average price target of $147.36. 
<img src="https://www.benzinga.com/files/images/story/2024/1727722841_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Airbnb. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Richard Clarke</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Underweight</td>
<td>$94.00</td>
<td>-</td>
</tr>
<tr>
<td>John Colantuoni</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$124.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$111.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Kevin Kopelman</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$125.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$121.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Lee Horowitz</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$90.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Mario Lu</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$134.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$120.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$130.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$130.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$129.00</td>
<td>$127.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Airbnb. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Airbnb compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Airbnb's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Airbnb's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ABNB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Airbnb analyst ratings.</a>
<h2>Get to Know Airbnb Better</h2>
Started in 2008, Airbnb is the world's largest online alternative accommodation travel agency, also offering booking services for boutique hotels and experiences. Airbnb's platform offered over 8 million active accommodation listings as of June 30, 2024. Listings from the company's over 5 million hosts are spread over almost every country in the world. In 2023, 50% of revenue was from the North American region. Transaction fees for online bookings account for all its revenue.
<h3>Airbnb: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Airbnb's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 10.63%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Airbnb's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.2% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Airbnb's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 6.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.18%, the company showcases effective utilization of assets.
Debt Management: Airbnb's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.28.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABNB

The Latest Analyst Ratings For Airbnb

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tharimmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) just reported results for the fourth quarter of 2023.<ul><li>Tharimmune reported earnings per share of -$5.84.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/thar-stock-earnings-tharimmune-for-q4-of-2023/">THAR Stock Earnings: Tharimmune Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

THAR Stock Earnings: Tharimmune Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re diving into the biggest pre-market stock movers that traders need to know about on Friday morning!



Moving stocks this morning are earnings reports, shutdown plans, clinical trial data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Akanda (NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is rocketing more than 94 % with heavy trading <a href="https://www.nasdaq.com/press-release/akanda-announces-stock-consolidation-2024-05-21">after a reverse split</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares are soaring over 71% alongside strong pre-market trading.</li>



<li>Cue Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/hlth-stock-quote/">HLTH</a>) stock is surging more than 42% <a href="https://finance.yahoo.com/news/cue-health-lay-off-remaining-165945667.html">despite shutdown plans</a>.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are rising over 35% on <a href="https://seekingalpha.com/news/4110109-verastem-stock-rallies-on-positive-data-for-pancreatic-cancer-drug-combo">positive pancreatic cancer drug data</a>.</li>



<li>Yoshitsu (NASDAQ:<a href="https://investorplace.com/stock-quotes/tklf-stock-quote/">TKLF</a>) stock is gaining more than 31% with heavy pre-market trading today.</li>



<li>Windtree Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/wint-stock-quote/">WINT</a>) shares are climbing over 24% despite a lack of news today.</li>



<li>Blue Star Foods (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsfc-stock-quote/">BSFC</a>) stock is increasing more than 23% with strong trading on Friday.</li>



<li>Innovative Eyewear (NASDAQ:<a href="https://investorplace.com/stock-quotes/lucy-stock-quote/">LUCY</a>) shares are heading over 18% higher with heavy trading today.</li>



<li>Merus (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrus-stock-quote/">MRUS</a>) stock is jumping 18% after reporting plans for its <a href="https://www.nasdaq.com/press-release/merus-announces-publication-of-abstracts-for-presentation-at-the-2024-ascor-annual-0">annual shareholder meeting</a>.</li>



<li>OneMedNet (NASDAQ:<a href="https://investorplace.com/stock-quotes/onmd-stock-quote/">ONMD</a>) shares are up 17% as it <a href="https://investorplace.com/2024/05/why-is-onemednet-onmd-stock-up-150-today/">continues to rally today</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Tharimmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock is crashing more than 93% ahead of a <a href="https://www.nasdaq.com/press-release/tharimmune-announces-1-for-15-reverse-stock-split-2024-05-22">reverse stock split</a>.</li>



<li>Soluna (NASDAQ:<a href="https://investorplace.com/stock-quotes/slnh-stock-quote/">SLNH</a>) shares are plummeting over 43% without any clear news today.</li>



<li>Sensei Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>) stock is diving more than 32% alongside <a href="https://www.nasdaq.com/press-release/sensei-biotherapeutics-presents-promising-clinical-data-from-phase-1-dose-escalation">Phase 1 clinical trial data</a>.</li>



<li>Barnes &amp; Noble Education (NYSE:<a href="https://investorplace.com/stock-quotes/bned-stock-quote/">BNED</a>) shares are tumbling over 22% <a href="https://www.businesswire.com/news/home/20240523398847/en/Barnes-Noble-Education-Announces-Preliminary-Fiscal-Year-2024-Results">alongside preliminary earnings</a>.</li>



<li>Cia Energetica DE Minas (NYSE:<a href="https://investorplace.com/stock-quotes/cig-stock-quote/">CIG</a>) stock is taking a more than 21% beating on Friday morning.</li>



<li>Summit Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/smmt-stock-quote/">SMMT</a>) shares are sliding 19% this morning.</li>



<li>Zoomcar (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcar-stock-quote/">ZCAR</a>) stock is dropping over 14% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318343841&amp;type=PDF&amp;symbol=ZCAR&amp;cdn=6950f0ca229d5d524e85e29caeb5189a&amp;companyName=Zoomcar+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-05-23">issuing an unsecured note</a>.</li>



<li>Akoustis Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/akts-stock-quote/">AKTS</a>) shares are decreasing more than 14% <a href="https://investorplace.com/2024/05/why-is-akoustis-technologies-akts-stock-up-158-today/">following a recent rally</a>.</li>



<li>Roadzen (NASDAQ:<a href="https://investorplace.com/stock-quotes/rdzn-stock-quote/">RDZN</a>) stock is falling 13% on Friday.</li>



<li>Solowin (NASDAQ:<a href="https://investorplace.com/stock-quotes/swin-stock-quote/">SWIN</a>) shares close out our pre-market stock movers down close to 13%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-may-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock is on the move Friday as investors prepare for the company&rsquo;s shares to undergo a reverse split when markets close today.



Tharimmune&nbsp;is enacting a <a href="https://www.nasdaq.com/press-release/tharimmune-announces-1-for-15-reverse-stock-split-2024-05-22">one-for-15 reverse stock split</a> for THAR shares. The shares will still trade under the THAR ticker but will switch to the new CUSIP number 432705309.



Tharimmune&nbsp;notes that this split will see it consolidate every 15 shares of its stock into a single share. The company says that this will leave it with 785,978 shares of THAR stock after the reverse split is complete.



<h2>What&rsquo;s Behind the THAR Reverse Stock Split?</h2>



Tharimmune&nbsp;is moving forward with this reverse stock split to boost the price of its shares. The company wants to boost its share price to reach the $1 minimum bid required to remain on The Nasdaq Capital Market. The stock was trading for 33 cents per share when markets closed yesterday.



Tharimmune&nbsp;wants to remain listed as it&rsquo;s still only a clinical-stage biotechnology company. That means it doesn&rsquo;t have a product to sell just yet. Remaining publicly listed is its goal leading up to a potential drug candidate release.



THAR stock is up 3.7% as of Friday morning ahead of the reverse split. However, the company&rsquo;s shares were down 34.5% year-to-date when markets closed on Thursday.



Investors will find more of the most recent stock market stories below!



We have all of the hottest stock market news traders need to know about on Friday! A few examples include what&rsquo;s happening with shares of Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) and Akanda&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock as well as the biggest pre-market stock movers this morning. All of this news is ready at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-akanda-akan-stock-up-133-today/">Why Is Akanda (AKAN) Stock Up 133% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-may-24th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Tharimmune (THAR) Stock Moving Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sensei Biotherapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101.



SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA. The company notes this has it being developed to treat solid cancer tumors.



The bad news for Sensei Biotherapeutics comes from its <a href="https://www.nasdaq.com/press-release/sensei-biotherapeutics-presents-promising-clinical-data-from-phase-1-dose-escalation">results in this trial</a>. The company notes that only a few patients of the 34 treated showed signs of improvement. That doesn&rsquo;t seem to be sitting well with SNSE stockholders today.



Dr.&nbsp;Shiraj Sen, a principal&nbsp;investigator in the SNS-101 study, said the following about the results.




&ldquo;The data show encouraging signs of clinical activity in a heterogeneous population of patients with advanced solid tumors, where you typically wouldn&rsquo;t expect to see clinical responses, especially in microsatellite stable colorectal and endometrial tumors.&rdquo;




<h2>SNSE Stock Market Movement on Friday</h2>



SNSE stock is seeing a decent amount of trading on Friday morning. This has more than 160,000 shares of the stock changing hands as of this writing. That&rsquo;s closing in on its daily average trading volume of about 208,000 shares.



SNSE stock is down 39.8% as of Friday morning. However, shares were up 83.5% year-to-date when markets closed yesterday.



Investors looking for more of the most recent stock market stories are in luck!



We have all of the hottest stock market news traders need to know about on Friday! That includes what&rsquo;s going on with shares of Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock, Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>)&nbsp;stock and Akanda&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock today. All of this info is good to go at the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-akanda-akan-stock-up-133-today/">Why Is Akanda (AKAN) Stock Up 133% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-sensei-biotherapeutics-snse-stock-down-40-today/">Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) stock is falling hard on Friday following the release of new clinical trial data for its metastatic pancreatic cancer treatment.



The company is <a href="https://finance.yahoo.com/news/verastem-oncology-announces-positive-initial-210100621.html">conducting a Phase 1/2 clinical trial</a> of avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel. The results were positive and that initially saw VSTM stock rally higher this morning.



However, investors quickly noticed the safety data included in these results. 19 of the 41 patients in the trial suffered from emergent serious adverse events. That includes 11 with grade &ge;3 events. Among these were blood bilirubin increase, biliary obstruction, febrile neutropenia, pulmonary embolism, sepsis, anaemia, pneumoperitoneum, septic shock, skin infection, malignant neoplasm progression and vomiting.



John Hayslip, Chief Medical Officer at Verastem, said the following about the clinical trial results.




&ldquo;Metastatic pancreatic cancer continues to be a challenging cancer to treat and these data support the intent behind the Therapeutic Accelerator Award that we received from PanCAN to develop new therapies faster and more efficiently than in historical studies.&rdquo;




<h2>VSTM Stock Movement on Friday</h2>



VSTM stock is experiencing heavy trading on Friday alongside this data. That has more than 10 million shares traded as of this writing. This is a massive surge compared to its daily average trading volume of about 134,000 shares.



VSTM stock is down 61.7% as of Friday morning!



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news traders need to know about on Friday! Among that is what has shares of Sensei Biotherapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>), Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) and Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) stock moving today. All of this news is available down below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-sensei-biotherapeutics-snse-stock-down-40-today/">Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-verastem-vstm-stock-down-62-today/">Why Is Verastem (VSTM) Stock Down 62% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Verastem (VSTM) Stock Down 62% Today?

Tharimmune announces $2.08M private placement

Tharimmune files for 1M common stock offering by selling stockholders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tharimmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) just reported results for the second quarter of 2024.<ul><li>Tharimmune reported earnings per share of -$2.42.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/thar-stock-earnings-tharimmune-for-q2-of-2024/">THAR Stock Earnings: Tharimmune Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

THAR Stock Earnings: Tharimmune Reported Results for Q2 2024

Tharimmune ( ($THAR) ) has provided an announcement. Tharimmune, Inc. has secured an exclusive license from Intract Pharma to develop an oral versi...

Tharimmune Expands Immunology Pipeline with Intract License

Tharimmune ( ($THAR) ) has shared an announcement. Tharimmune, Inc. has announced its intent to acquire Intract Pharma Limited, aiming to purchase ...

Tharimmune Announces Intent to Acquire Intract Pharma

AKAN

AKTS

BNED

BSFC

HLTH

LUCY

MRUS

NCPL

ONMD

RDZN

SLNH

SMMT

SNSE

SWIN

THAR

TKLF

VSTM

WINT

ZCAR

Biotech

Events

Press Releases

Tharimmune to Present at 2024 BIO International Convention

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Comments

Tharimmune

Noticias

Últimas noticias sobre Tharimmune (NASDAQ:THAR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL